Trial Profile
A Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+) Negative Stage II-III Breast Cancers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2015
Price :
$35
*
At a glance
- Drugs Anti-CD3-anti-HER2-activated T-cells (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 08 Jun 2013 New source identified and integrated (Barbara Ann Karmanos Cancer Institute: 2010-056).
- 15 Aug 2012 New trial record